Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Hypertension ; 79(8): 1738-1754, 2022 08.
Artículo en Inglés | MEDLINE | ID: mdl-35607996

RESUMEN

BACKGROUND: We have demonstrated that protein aggregation plays a pivotal role in the pathophysiology of preeclampsia and identified several aggregated proteins in the circulation of preeclampsia patients, the most prominent of which is the serum protein TTR (transthyretin). However, the mechanisms that underlie protein aggregation remain poorly addressed. METHODS: We examined TTR aggregates in hypoxia/reoxygenation-exposed primary human trophoblasts (PHTs) and the preeclampsia placenta using complementary approaches, including a novel protein aggregate detection assay. Mechanistic analysis was performed in hypoxia/reoxygenation-exposed PHTs and Ttr transgenic mice overexpressing transgene-encoded wild-type human TTR or Ttr-/- mice. High-resolution ultrasound analysis was used to measure placental blood flow in pregnant mice. RESULTS: TTR aggregation was inducible in PHTs and the TCL-1 trophoblast cell line by endoplasmic reticulum stress inducers or autophagy-lysosomal disruptors. PHTs exposed to hypoxia/reoxygenation showed increased intracellular BiP (binding immunoglobulin protein), phosphorylated IRE1α (inositol-requiring enzyme-1α), PDI (protein disulfide isomerase), and Ero-1, all markers of the unfolded protein response, and the apoptosis mediator caspase-3. Blockade of IRE1α inhibited hypoxia/reoxygenation-induced upregulation of Ero-1 in PHTs. Excessive unfolded protein response activation was observed in the early-onset preeclampsia placenta. Importantly, pregnant human TTR mice displayed aggregated TTR in the junctional zone of the placenta and severe preeclampsia-like features. High-resolution ultrasound analysis revealed low blood flow in uterine and umbilical arteries in human TTR mice compared with control mice. However, Ttr-/- mice did not show any pregnancy-associated abnormalities. CONCLUSIONS: These observations in the preeclampsia placenta, cultured trophoblasts, and Ttr transgenic mice indicate that TTR aggregation is an important causal contributor to preeclampsia pathophysiology.


Asunto(s)
Preeclampsia , Trofoblastos , Animales , Proteínas Portadoras/metabolismo , Retículo Endoplásmico/metabolismo , Estrés del Retículo Endoplásmico , Endorribonucleasas/metabolismo , Femenino , Humanos , Hipoxia/metabolismo , Ratones , Ratones Transgénicos , Placenta/metabolismo , Preeclampsia/genética , Preeclampsia/metabolismo , Prealbúmina/análisis , Prealbúmina/genética , Prealbúmina/metabolismo , Embarazo , Agregado de Proteínas , Proteínas Serina-Treonina Quinasas , Trofoblastos/metabolismo
2.
Biochem Biophys Res Commun ; 348(3): 889-97, 2006 Sep 29.
Artículo en Inglés | MEDLINE | ID: mdl-16904635

RESUMEN

The amyloidoses are the extracellular subset of a group of diseases in which in vivo protein misfolding leads to a pathologic gain of function, i.e., aggregation leading to protein deposition, with subsequent tissue damage. Wild-type and mutant transthyretins (TTR) are the etiologic agents in prototypic systemic amyloidoses. We describe a cell-based assay that measures the cytotoxicity of physiologic concentrations of the amyloidogenic Val30Met TTR variant (V30M TTR) using cells of the same lineage as the in vivo tissue target of amyloid deposition. We have utilized the assay to screen small molecules for their capacity to inhibit the TTR-induced cell damage. We compared the inhibitory activity of each compound with its ability to prevent TTR fibril formation in vitro. Our results emphasize the importance of screening compounds under physiologic conditions. Moreover, if a common conformational intermediate is responsible for cell death in all the amyloid diseases, the cell-based assay has the potential to aid in the discovery of compounds useful in the treatment of amyloidoses caused by other misfolded proteins as well as those caused by TTR.


Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Prealbúmina/antagonistas & inhibidores , Prealbúmina/metabolismo , Amiloidosis/tratamiento farmacológico , Amiloidosis/genética , Amiloidosis/metabolismo , Línea Celular Tumoral , Linaje de la Célula/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Diflunisal/análogos & derivados , Diflunisal/farmacología , Evaluación Preclínica de Medicamentos , Humanos , Metionina/genética , Microfibrillas/efectos de los fármacos , Neuronas/citología , Neuronas/efectos de los fármacos , Prealbúmina/genética , Prealbúmina/toxicidad , Resveratrol , Estilbenos/farmacología , Valina/genética
3.
Trends Biochem Sci ; 28(11): 585-92, 2003 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-14607088

RESUMEN

Certain human diseases are associated with proteins that misfold and exhibit decreased solubility under physiological conditions. They result either from mutations that change the amino acid sequence of a protein, or from misfolded wild-type proteins, such as in Parkinson's disease and Alzheimer's disease. One subset--the amyloidoses--cause extracellular deposits that stain with the dye Congo red. Another subset is associated with intracellular deposits with non-Congophilic nuclear or cytoplasmic inclusions. Purified, recombinantly produced versions of some of the proteins that form intracellular aggregates can also display Congophilia, as well as other properties associated with the in vivo amyloidoses when examined under non-physiological conditions in vitro. Some of these purified proteins or protein fragments have never been identified as pathogenic in humans or animals. Despite potentially shared thermodynamic and kinetic processes involving the target molecules, the biology of these two subsets differs significantly.


Asunto(s)
Amiloide/química , Amiloidosis/patología , Rojo Congo/metabolismo , Conformación Proteica , Amiloide/metabolismo , Animales , Rojo Congo/química , Humanos , Técnicas In Vitro , Pliegue de Proteína
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA